No­vo touts ear­ly da­ta for next-gen oral weight loss drug as it out­lines next steps

No­vo Nordisk’s oral amy­cretin showed a 13.1% weight loss in pa­tients af­ter just 12 weeks in a small Phase I tri­al, the com­pa­ny re­vealed at its cap­i­tal mar­kets day in Copen­hagen on Thurs­day.

The drug, a co-ag­o­nist to both GLP-1 and amylin re­cep­tor, is al­so be­ing test­ed in its sub­cu­ta­neous form. That Phase I tri­al is set to read out next year, at which point clin­i­cal de­vel­op­ment plans will be de­fined.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER